T Cell Sciences deal

TCEL amended its product development and distribution agreement with AB Astra covering products using TCEL's T cell receptor (TCAR) technology. Under the amended agreement, Astra will assume responsibility for the manufacturing of the two monoclonal candidates, TM27 and TM29, previously manufactured by TCEL. As a result, TCEL will receive a lower percentage of net sales.

The original 1992 agreement called for TCEL to receive about $15 million in funding in the initial years of the program, with up to $17 million in additional milestone payments. Astra's funding commitment remains unchanged. ...